Form 8-K - Current report:
SEC Accession No. 0000950170-24-008123
Filing Date
2024-01-29
Accepted
2024-01-29 07:11:53
Documents
14
Period of Report
2024-01-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K engn-20240129.htm   iXBRL 8-K 42107
2 EX-99.1 engn-ex99_1.htm EX-99.1 79053
3 GRAPHIC img7790613_0.jpg GRAPHIC 14394
  Complete submission text file 0000950170-24-008123.txt   300557

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20240129.xsd EX-101.SCH 47083
15 EXTRACTED XBRL INSTANCE DOCUMENT engn-20240129_htm.xml XML 6603
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 24570076
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)